Curis Inc. (CRIS)

2.02
NASDAQ : Health Technology
Prev Close 2.11
Day Low/High 2.01 / 2.18
52 Wk Low/High 0.60 / 2.90
Avg Volume 186.50K
Exchange NASDAQ
Shares Outstanding 33.20M
Market Cap 70.06M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
10 ASCO '13 Abstracts You Can Read Right Now

10 ASCO '13 Abstracts You Can Read Right Now

Get a head start on searching through ASCO abstracts with these 10 summaries.

Curis Announces Approval Of Erivedge(R) In Australia

Curis Announces Approval Of Erivedge(R) In Australia

Expands Global Erivedge Patient Access and Commercial Opportunity

Curis Reports First Quarter 2013 Financial Results

Curis Reports First Quarter 2013 Financial Results

-- Management to Host Conference Call Today at 9:00 a.m. EDT --

3 Under-$10 Stocks Making Big Moves

3 Under-$10 Stocks Making Big Moves

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

16 Stocks Under $5 Trading At Discounts To Target Price

16 Stocks Under $5 Trading At Discounts To Target Price

Looking for undervalued stocks? Value investors look for opportunities to buy stocks that are trading at significant discounts to their [...]

Curis Announces Appointment Of Kenneth Pienta, M.D. To Board Of Directors

Curis Announces Appointment Of Kenneth Pienta, M.D. To Board Of Directors

Brings Over 20 Years of Experience in Oncology Clinical Practice and Cancer Research With Expertise in Precision Approaches to Cancer Therapies

Curis Reports Fourth Quarter And Year-End 2012 Financial Results

Curis Reports Fourth Quarter And Year-End 2012 Financial Results

Conference Call to Discuss Results and Provide 2013 Outlook Today at 9:00 a.m. EST

Curis Announces Dosing Of First Patient In Phase I Clinical Trial Of Dual PI3 Kinase And HDAC Inhibitor CUDC-907

Curis Announces Dosing Of First Patient In Phase I Clinical Trial Of Dual PI3 Kinase And HDAC Inhibitor CUDC-907

Curis Earns $350,000 in Milestone Payments From The Leukemia & Lymphoma Society

Curis Achieves CUDC-907 Milestones Under Its Agreement With The Leukemia & Lymphoma Society

Curis Achieves CUDC-907 Milestones Under Its Agreement With The Leukemia & Lymphoma Society

IND Filed to Begin Phase I Clinical Testing of CUDC-907

4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

Stocks that are making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility.

Curis Inc. Stock Downgraded (CRIS)

Curis Inc. Stock Downgraded (CRIS)

Curis (Nasdaq:CRIS) has been downgraded by TheStreet Ratings from from a hold to sell.

Curis And Debiopharm Announce Initiation Of Phase I-II Clinical Study Of HSP90 Inhibitor Debio 0932

Curis And Debiopharm Announce Initiation Of Phase I-II Clinical Study Of HSP90 Inhibitor Debio 0932

Study to Test Debio 0932 in Patients With Advanced Non-Small Cell Lung Cancer

Curis Inc. Stock Upgraded (CRIS)

Curis Inc. Stock Upgraded (CRIS)

Curis (Nasdaq:CRIS) has been upgraded by TheStreet Ratings from a sell to hold.

FDA Approves Roche, Curis Skin-Cancer Drug

FDA Approves Roche, Curis Skin-Cancer Drug

Roche and Curis' drug is the first approved therapy for advanced basal cell carcinoma.

Play TheStreet's FDA Drug-Approval Contest

Play TheStreet's FDA Drug-Approval Contest

The FDA will issue approval decisions on 17 drugs over the next four months. How well can you predict which drugs will be approved or rejected?

TheStreet Quant Rating: D- (Sell)